Author Topic: Roche touts Ocrevus benefits in treating MS early--competing with Kesimpta  (Read 28 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9670
  • MS diagnosed 1980
  • Location: Pacific Northwest
From FiercePharma (April 21, 2021)--"Roche, playing defense against Novartis' Kesimpta, touts Ocrevus benefits in treating MS early":

Although this article is over a year old, it contains an interesting bit of data that surprised me:

About 80% of patients adhered to twice-yearly dosing of Ocrevus after their second year of treatment. That was compared with 54% for other IV drugs, 35% for intramuscular and under-the-skin injectables, and 55% for orals.[/size]
[size=78%]Only 35% of the MS patients on the intramuscular and under-the-skin injectables stay on them after the second year.  Does this dismal adherence indicate a vote of no-confidence in those drugs, or is it more that people find doing the injections to be difficult?[/size]

MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.


Related Topics

  Subject / Started by Replies Last post
0 Replies
Last post July 16, 2017, 04:27:18 pm
by agate
0 Replies
Last post January 26, 2018, 09:46:57 pm
by agate
1 Replies
Last post November 03, 2018, 07:59:00 am
by agate
0 Replies
Last post October 03, 2018, 08:03:12 pm
by agate
0 Replies
Last post September 17, 2021, 08:18:27 pm
by agate